Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0FC8O
|
|||
| Former ID |
DIB001493
|
|||
| Drug Name |
DWP-05195
|
|||
| Synonyms |
DWJ-204; DWP-0519
Click to Show/Hide
|
|||
| Indication | Neuropathic pain [ICD-11: 8E43.0] | Phase 2 | [1] | |
| Company |
Daewoong Pharmaceutical Co Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transient receptor potential cation channel V1 (TRPV1) | Target Info | Antagonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Inflammatory mediator regulation of TRP channels | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Trk receptor signaling mediated by the MAPK pathway | |||
| Trk receptor signaling mediated by PI3K and PLC-gamma | ||||
| Reactome | TRP channels | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01557010) Evaluate the Efficacy and Safety of DWP05195 in Subjects With Post-Herpetic Neuralgia. U.S. National Institutes of Health. | |||
| REF 2 | TRPV1 Antagonists as Analgesic Agents. The Open Pain Journal, 2013, 6, (Suppl 1: M11), 108-118 . | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.